<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39361539</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>39</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Differences in COVID-19 Outpatient Antiviral Treatment Among Adults Aged ≥65 Years by Age Group - National Patient-Centered Clinical Research Network, United States, April 2022-September 2023.</ArticleTitle><Pagination><StartPage>876</StartPage><EndPage>882</EndPage><MedlinePgn>876-882</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7339a3</ELocationID><Abstract><AbstractText>Adults aged ≥65 years experience the highest risk for COVID-19-related hospitalization and death, with risk increasing with increasing age; outpatient antiviral treatment reduces the risk for these severe outcomes. Despite the proven benefit of COVID-19 antiviral treatment, information on differences in use among older adults with COVID-19 by age group is limited. Nonhospitalized patients aged ≥65 years with COVID-19 during April 2022-September 2023 were identified from the National Patient-Centered Clinical Research Network. Differences in use of antiviral treatment among patients aged 65-74, 75-89, and ≥90 years were assessed. Multivariable logistic regression was used to estimate the association between age and nonreceipt of antiviral treatment. Among 393,390 persons aged ≥65 years, 45.9% received outpatient COVID-19 antivirals, including 48.4%, 43.5%, and 35.2% among those aged 65-75, 76-89, and ≥90 years, respectively. Patients aged 75-89 and ≥90 years had 1.17 (95% CI = 1.15-1.19) and 1.54 (95% CI = 1.49-1.61) times the adjusted odds of being untreated, respectively, compared with those aged 65-74 years. Among 12,543 patients with severe outcomes, 2,648 (21.1%) had received an outpatient COVID-19 antiviral medication, compared with 177,874 (46.7%) of 380,847 patients without severe outcomes. Antiviral use is underutilized among adults ≥65 years; the oldest adults are least likely to receive treatment. To prevent COVID-19-associated morbidity and mortality, increased use of COVID-19 antiviral medications among older adults is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Claire M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Melisa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>DeSantis</LastName><ForeName>Carol E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Bertumen</LastName><ForeName>J Bradford</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Faraz S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Carton</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Cowell</LastName><ForeName>Lindsay G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Jefferson M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Pragna</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Melissa Briggs</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Block</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koumans</LastName><ForeName>Emily H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Faraz S. Ahmad reports receipt of consulting fees and editorial support from Pfizer. Thomas W. Carton reports receipt of grant support from the Task Force for Global Health. No other potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39361539</ArticleId><ArticleId IdType="pmc">PMC11449269</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7339a3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor CA, Patel K, Pham, H, et al. COVID-19–associated hospitalizations among U.S. adults aged ≥18 years—COVID-NET, 12 states, October 2023–April 2024. MMWR Morb Mortal Wkly Rep 2024;73:869–75. 10.15585/mmwr.mm7240a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7240a3</ArticleId><ArticleId IdType="pmc">PMC10564325</ArticleId><ArticleId IdType="pubmed">37796744</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. COVID-19: underlying conditions and the higher risk for severe COVID-19. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html#:~:text=Having%20multiple%20conditions%20was%20also,of%20patients)%20increased%20with%20age</Citation></Reference><Reference><Citation>Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study. Ann Intern Med 2023;176:77–84. 10.7326/M22-2141</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2141</ArticleId><ArticleId IdType="pmc">PMC9753458</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Cisewski JA, Xu J, Anderson RN. COVID-19 mortality update—United States, 2022. MMWR Morb Mortal Wkly Rep 2023;72:493–6. 10.15585/mmwr.mm7218a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7218a4</ArticleId><ArticleId IdType="pmc">PMC10168601</ArticleId><ArticleId IdType="pubmed">37141157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock AD, Kissler S, Mehrotra A, et al. Clinical risk and outpatient therapy utilization for COVID-19 in the Medicare population. JAMA Health Forum 2024;5:e235044. 10.1001/jamahealthforum.2023.5044</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2023.5044</ArticleId><ArticleId IdType="pmc">PMC10818223</ArticleId><ArticleId IdType="pubmed">38277170</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer TK, Koumans EH, Skillen EL, et al. Racial and ethnic disparities in outpatient treatment of COVID-19—United States, January–July 2022. MMWR Morb Mortal Wkly Rep 2022;71:1359–65. 10.15585/mmwr.mm7143a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7143a2</ArticleId><ArticleId IdType="pmc">PMC9620572</ArticleId><ArticleId IdType="pubmed">36301738</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JW, Rogers JR, Her Q, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care 2017;55:1046–51. 10.1097/MLR.0000000000000824</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000824</ArticleId><ArticleId IdType="pubmed">29087983</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol-Elkaim B, Dryden-Peterson S, Miller DR, Koh HK, Geller AC. Oral antiviral therapy utilization among adults with recent COVID-19 in the United States. J Gen Intern Med 2023;38:1717–21. 10.1007/s11606-023-08106-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-023-08106-6</ArticleId><ArticleId IdType="pmc">PMC9973233</ArticleId><ArticleId IdType="pubmed">36853557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun N, Hua CL, Qiu X, Brown JS. Determinants of COVID-19 testing among late middle-aged and older adults: applying the health belief model. Aging Health Res 2022;2:100066. 10.1016/j.ahr.2022.100066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahr.2022.100066</ArticleId><ArticleId IdType="pmc">PMC8949689</ArticleId><ArticleId IdType="pubmed">35350777</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DJ, Lambrou A, Patel P. SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals. MMWR Morb Mortal Wkly Rep 2023;72:1357–64. 10.15585/mmwr.mm7251a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7251a1</ArticleId><ArticleId IdType="pmc">PMC10754268</ArticleId><ArticleId IdType="pubmed">38127665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>